Anebulo Pharmaceuticals, Inc. has named Simon Allen as Chief Executive Officer and a member of the company's Board of Directors, effective February 1st, 2022. Mr. Allen succeeds Daniel Schneeberger, MD, who has resigned as CEO and as a Director as of that same date. Since March 2019, Mr. Allen has served as Chief Business Officer of Ambrx Biopharma Inc., a position he previously held from 2010 through 2015.

Ambrx is an engineered precision biologics company developing antibody-drug conjugate and immune-oncology conjugate candidates for breast cancer, gastric cancer and other solid tumors.